



BLA 125476/S-066  
BLA 761133/S-014

## SUPPLEMENT APPROVAL

Takeda Pharmaceuticals, U.S.A., Inc.  
Attention: Robert Solinga  
Director, Global Regulatory Affairs  
500 Kendall Street  
Cambridge, MA 02142

Dear Robert Solinga:

Please refer to your supplemental biologics license application (sBLA) received January 26, 2026, and your amendments, submitted under section 351(a) of the Public Health Service Act for Entyvio (vedolizumab) for injection, Entyvio (vedolizumab) injection, for subcutaneous use, and Entyvio Pen (vedolizumab) injection, for subcutaneous use.

This Prior Approval sBLA provides for updates to the WARNINGS AND PRECAUTIONS, *Infections* subsection to add postmarketing cases of systemic bacterial, fungal, viral, and parasitic opportunistic infections.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,<sup>1</sup> that is identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Andrew Chi, Regulatory Project Manager, at [Andrew.Chi@fda.hhs.gov](mailto:Andrew.Chi@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology (DG)  
Office of Immunology and Inflammation (OII)  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

JOYCE A KORVICK  
02/25/2026 07:11:10 PM